LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

11.87 0.34

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.4

Máximo

12.01

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.506 49.701
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+67.36% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.1B
Abertura anterior	11.53
Fecho anterior	11.87

Sentimento de Notícias

By Acuity

10%

90%

8 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

14.24 / 14.78 Suporte e Resistência

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

19 de mai. de 2026, 20:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 de mai. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Ganhos

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

19 de mai. de 2026, 23:10 UTC

Conversa de Mercado

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 de mai. de 2026, 22:02 UTC

Ganhos

ZTO Express (Cayman): Di Xu to Resign From Board

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 de mai. de 2026, 22:01 UTC

Ganhos

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 de mai. de 2026, 22:00 UTC

Ganhos

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 de mai. de 2026, 21:37 UTC

Ganhos

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 de mai. de 2026, 21:31 UTC

Aquisições, Fusões, Aquisições de Empresas

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 de mai. de 2026, 21:01 UTC

Ganhos

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 de mai. de 2026, 20:58 UTC

Ganhos

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 de mai. de 2026, 20:46 UTC

Ações em Alta

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 de mai. de 2026, 20:43 UTC

Conversa de Mercado

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 de mai. de 2026, 20:34 UTC

Ganhos

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q EPS 5c >JHX

19 de mai. de 2026, 20:32 UTC

Ganhos

James Hardie Industries 4Q Sales $1.4B >JHX

19 de mai. de 2026, 20:21 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Buy Empower Semiconductor for $1.5B

19 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 de mai. de 2026, 20:13 UTC

Conversa de Mercado

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 de mai. de 2026, 20:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 de mai. de 2026, 20:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 de mai. de 2026, 19:23 UTC

Conversa de Mercado

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

67.36% parte superior

Previsão para 12 meses

Média 20 USD 67.36%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimento

By Acuity

8 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.